Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.50
ISIS's Cash to Debt is ranked higher than
58% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. ISIS: 1.50 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.24   Max: 4.87
Current: 1.5

0.24
4.87
Equity to Asset 0.29
ISIS's Equity to Asset is ranked higher than
54% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ISIS: 0.29 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.85   Max: 0.76
Current: 0.29

-0.85
0.76
F-Score: 4
Z-Score: 6.80
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.02
ISIS's Operating margin (%) is ranked higher than
80% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. ISIS: -11.02 )
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91   Max: -12.18
Current: -11.02

-438.91
-12.18
Net-margin (%) -9.82
ISIS's Net-margin (%) is ranked higher than
80% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. ISIS: -9.82 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33   Max: 127.52
Current: -9.82

-334.33
127.52
ROE (%) -7.54
ISIS's ROE (%) is ranked higher than
81% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. ISIS: -7.54 )
ISIS' s 10-Year ROE (%) Range
Min: -280.13   Max: 86.43
Current: -7.54

-280.13
86.43
ROA (%) -2.80
ISIS's ROA (%) is ranked higher than
83% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. ISIS: -2.80 )
ISIS' s 10-Year ROA (%) Range
Min: -59.44   Max: 25.19
Current: -2.8

-59.44
25.19
ROC (Joel Greenblatt) (%) -27.42
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. ISIS: -27.42 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -800.86   Max: -54.5
Current: -27.42

-800.86
-54.5
Revenue Growth (3Y)(%) 22.50
ISIS's Revenue Growth (3Y)(%) is ranked higher than
89% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ISIS: 22.50 )
ISIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -39.4   Max: 83.7
Current: 22.5

-39.4
83.7
EBITDA Growth (3Y)(%) -30.30
ISIS's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ISIS: -30.30 )
ISIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.6   Max: 61.3
Current: -30.3

-49.6
61.3
EPS Growth (3Y)(%) -27.00
ISIS's EPS Growth (3Y)(%) is ranked higher than
62% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. ISIS: -27.00 )
ISIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.2   Max: 117.8
Current: -27

-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ISIS Guru Trades in Q2 2014

Murray Stahl 17,000 sh (unchged)
Ron Baron Sold Out
Jim Simons Sold Out
George Soros Sold Out
» More
Q3 2014

ISIS Guru Trades in Q3 2014

Murray Stahl 17,000 sh (unchged)
» More
Q4 2014

ISIS Guru Trades in Q4 2014

Joel Greenblatt 8,745 sh (New)
Paul Tudor Jones 6,473 sh (New)
Murray Stahl 17,000 sh (unchged)
» More
Q1 2015

ISIS Guru Trades in Q1 2015

Murray Stahl 17,000 sh (unchged)
Paul Tudor Jones 6,390 sh (-1.28%)
Joel Greenblatt 7,892 sh (-9.75%)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 29.33
ISIS's P/B is ranked lower than
54% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ISIS: 29.33 )
ISIS' s 10-Year P/B Range
Min: 3   Max: 1710
Current: 29.33

3
1710
P/S 32.11
ISIS's P/S is ranked higher than
62% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. ISIS: 32.11 )
ISIS' s 10-Year P/S Range
Min: 4.33   Max: 84.47
Current: 32.11

4.33
84.47
Current Ratio 8.33
ISIS's Current Ratio is ranked higher than
83% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. ISIS: 8.33 )
ISIS' s 10-Year Current Ratio Range
Min: 2.49   Max: 9.89
Current: 8.33

2.49
9.89
Quick Ratio 8.26
ISIS's Quick Ratio is ranked higher than
84% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ISIS: 8.26 )
ISIS' s 10-Year Quick Ratio Range
Min: 2.49   Max: 9.89
Current: 8.26

2.49
9.89
Days Sales Outstanding 39.55
ISIS's Days Sales Outstanding is ranked higher than
91% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. ISIS: 39.55 )
ISIS' s 10-Year Days Sales Outstanding Range
Min: 1.87   Max: 86.04
Current: 39.55

1.87
86.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 521.23
ISIS's Price/Net Cash is ranked higher than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. ISIS: 521.23 )
ISIS' s 10-Year Price/Net Cash Range
Min: 4.75   Max: 489.77
Current: 521.23

4.75
489.77
Price/Net Current Asset Value 52.13
ISIS's Price/Net Current Asset Value is ranked higher than
59% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. ISIS: 52.13 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.49   Max: 705.5
Current: 52.13

4.49
705.5
Price/Tangible Book 31.66
ISIS's Price/Tangible Book is ranked lower than
56% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. ISIS: 31.66 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 2.82   Max: 216.67
Current: 31.66

2.82
216.67
Price/Median PS Value 2.55
ISIS's Price/Median PS Value is ranked higher than
69% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ISIS: 2.55 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.15
Current: 2.55

0.21
5.15
Earnings Yield (Greenblatt) -0.30
ISIS's Earnings Yield (Greenblatt) is ranked higher than
84% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ISIS: -0.30 )
ISIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 0.3
Current: -0.3

0.2
0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISI.Germany, ISIS.Switzerland,
Isis Pharmaceuticals Inc was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business segments are Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 31 drugs in development. Company's ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company's drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 

More From Other Websites
Is the Stock Market Due for a Correction? May 18 2015
ISIS PHARMACEUTICALS INC Financials May 13 2015
4 Biotech Stocks Could Have Big Upside Before Russell Index Changes May 12 2015
10-Q for Isis Pharmaceuticals, Inc. May 07 2015
Another Goliath Partners With Isis Pharmaceuticals May 06 2015
Is Isis just what the doctor ordered? May 06 2015
Isis Pharmaceuticals' Q1 Loss Narrower than Expected - Analyst Blog May 06 2015
Isis Pharmaceuticals (ISIS) Earnings Report: Q1 2015 Conference Call Transcript May 06 2015
Isis Reports Financial Results and Highlights for First Quarter 2015 May 05 2015
ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015
Isis reports 1Q loss May 05 2015
Isis reports 1Q loss May 05 2015
Isis Reports Financial Results and Highlights for First Quarter 2015 May 05 2015
Isis Pharmaceuticals (ISIS) Stock Rises After CEO Appears on Jim Cramer's 'Mad Money' May 05 2015
Q1 2015 Isis Pharmaceuticals Inc Earnings Release - Before Market Open May 05 2015
Jim Cramer's Top Takeaways: Dow Chemical, Isis Pharmaceuticals, Wells Fargo May 05 2015
Jim Cramer's 'Mad Money' Recap: Buffett 'Halo,' Dollar Top, Growth Stocks Spurred Rally May 04 2015
Will Isis Pharmaceuticals (ISIS) Disappoint in Q1 Earnings? - Analyst Blog May 04 2015
Isis Pharma Up As Bayer Licenses Thrombosis Drug May 04 2015
ISIS Pharmaceuticals Cuts License Deal With Bayer AG May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK